News
AORT
13.35
+4.38%
0.56
Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?
Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 6d ago
Wall Street Analysts Predict a 173% Upside in Artivion (AORT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 173.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translat...
Zacks · 11/09 14:55
Artivion to Participate in Upcoming Investor Conferences
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
PR Newswire · 11/08 21:25
--Needham Adjusts Price Target on Artivion to $23 From $28, Maintains Buy Rating
--Needham Adjusts Price Target on Artivion to $23 From $28, Maintains Buy Rating
MT Newswires · 11/04 12:52
Under Armour To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Benzinga · 11/04 12:25
Needham Maintains Buy on Artivion, Lowers Price Target to $23
Benzinga · 11/04 10:01
Artivion Non-GAAP EPS of -$0.05, revenue of $76.8M
Seekingalpha · 11/03 20:36
Artivion Q3 EPS $(0.05) Beats $(0.11) Estimate, Sales $76.80M Beat $76.19M Estimate
Benzinga · 11/03 20:20
Artivion Reports Third Quarter 2022 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the third quarter ended September 30, 2022.
PR Newswire · 11/03 20:05
-- Earnings Flash (AORT) ARTIVION Reports Q3 Revenue $76.8M, vs. Street Est of $76.2M
-- Earnings Flash (AORT) ARTIVION Reports Q3 Revenue $76.8M, vs. Street Est of $76.2M
MT Newswires · 11/03 16:35
-- Earnings Flash (AORT) ARTIVION Reports Q3 Loss $-0.05, vs. Street Est of $-0.05
-- Earnings Flash (AORT) ARTIVION Reports Q3 Loss $-0.05, vs. Street Est of $-0.05
MT Newswires · 11/03 16:25
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes. On that day, the Compan...
PR Newswire · 10/20 12:25
This Senator Just Bought Up To $100K In Artivion Stock
The Office of Senator Tina Smith reported a purchase of Artivion (NYSE:AORT) stock on October 17, 2022. According to the October filing, the transaction was made on October 17, 2022.
Benzinga · 10/18 17:03
Morgan Stanley Trims Artivion's Price Target to $14 From $16, Reiterates Equalweight Rating
Morgan Stanley Trims Artivion's Price Target to $14 From $16, Reiterates Equalweight Rating
MT Newswires · 10/11 11:19
BRIEF-Elizabeth Hoff Joins Artivion Board Of Directors
BRIEF-Elizabeth Hoff Joins Artivion Board Of Directors
Reuters · 09/29 20:12
This Analyst Says Artivion's Sell Off Seems Overdone After Trial Halt
Benzinga · 09/26 19:31
BRIEF-Juniper Investment Company Reports 5.2% Stake In Artivion Common Stock, As Of September 23, 2022 - SEC Filing
BRIEF-Juniper Investment Company Reports 5.2% Stake In Artivion Common Stock, As Of September 23, 2022 - SEC Filing
Reuters · 09/26 19:00
Oppenheimer Maintains Outperform Rating for Artivion: Here's What You Need To Know
Oppenheimer has decided to maintain its Outperform rating of Artivion (NYSE:AORT) and lower its price target from $35.00 to $25.00. Shares of Artivion are trading up 1.43% over the last 24 hours, at $13.50 per share. A move to $25.00 would account for a 85.19% increase from the current share price.
Benzinga · 09/26 16:10
4 Analysts Have This to Say About Artivion
Artivion (NYSE:AORT) has observed the following analyst ratings within the last quarter:
Benzinga · 09/26 14:14
Oppenheimer Maintains Outperform on Artivion, Lowers Price Target to $25
Oppenheimer analyst Suraj Kalia maintains Artivion (NYSE:AORT) with a Outperform and lowers the price target from $35 to $25.
Benzinga · 09/26 12:31
More
Webull provides a variety of real-time AORT stock news. You can receive the latest news about Cryolife Inc through multiple platforms. This information may help you make smarter investment decisions.
About AORT
Artivion, Inc. is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. It operates in two segments: Medical Devices and Preservation Services. It has four product families: aortic stents and stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stents and stent grafts include JOTEC stent grafts and surgical products (collectively, JOTEC Products), the Ascyrus Medical Dissection Stent (AMDS) hybrid prosthesis, and the NEXUS endovascular stent graft system (NEXUS). Surgical sealants include BioGlue Surgical Adhesive (BioGlue) products. It also sells or distributes PhotoFix bovine surgical patches, CardioGenesis cardiac laser therapy, Therion chorioamniotic allografts, and PerClot hemostatic powder.